December 1, 2010
Bookmark and Share  



This week the HCV Advocate Eblast contains the following updated files and information:


1. Newsletter:

  • AASLD 2010 Conference – Part 1
    Alan Franciscus, Editor-in-Chief

This year’s AASLD Conference was chock-full of information about the Direct Acting Antivirals (DDAs) being developed to treat hepatitis C – some pretty amazing results.


  • IL28B Gene Highlighted at AASLD
    Liz Highleyman

IL28B is an important variation on a gene that can help predict and guide treatment.  There are also pitfalls to using this test, but big questions remains as to how this information will apply to the new DAAs.


  • HealthWise: 2010 Liver Meeting Update
    Lucinda Porter, RN

Lucinda provides her unique perspective on this year’s AASLD Conference. 


  • HCV Snapshots
    Lucinda Porter, RN

Lucinda discusses various studies such as pain management in the cirrhotic patient, treatment in people with recurrence of HCV after transplantation and the affect of alcohol on the liver. 


2. Redesigned Drug Pipeline

  • Check out our newly designed and hopefully easier to access HCV Drug Pipeline.  We would be interested in your opinion of the new design and ease of access.  Send your email to


3. HBV Journal Review

  • This month’s journal has extended coverage on the risks of breastfeeding and antiviral use in mother-to-child HBV transmission.


4. "Disability & Benefits: Rumors, Myths, and a Little Truth"

  • Get the skinny on the myths surrounding Disability in Jacques Chamber’s monthly column.


5. Top 10 HCV Downloads and HBV Downloads of the Month

  • Find out about the articles and factsheets others are reading—from disability issues to treatment side effect management. 





Alan Franciscus
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate
Editor-in-Chief, HBV Advocate


**Questions and Comments: Questions and/or comments can be directed to

**To receive the eblast in your email inbox simply send an e-mail to: with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.